NEW YORK, Sept. 11, 2023 /PRNewswire/ -- The antiemetic drug market size is expected to grow by USD 1.63 billion from 2022 to 2027. In addition, the growth of the market will progress at a CAGR of 6.47% during the forecast period, according to Technavio Research. The market has been segmented by Application (Chemotherapy, Surgery, Gastroenteritis, and Others), the drug Class (5-hydroxytryptamine 3 (5-HT 3) receptor antagonist, dopamine antagonist, neurokinin-1 (NK 1) receptor antagonist, cannabinoid receptor antagonist, and others), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 37% to the growth of the global market during the forecast period. The US, Canada, and Mexico are major contributors to the market growth in the region. It represents a key region for the development, manufacturing, and consumption of antiemetic drugs. Furthermore, various leading pharmaceuticals are based in North America, developing and manufacturing antiepileptic medicines. Hence, such factors drive the antiemetic drug market in the North American region during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report
Company Profile:
Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc.
Boehringer Ingelheim International GmbH - The company offers an antiemetic drug, namely OFEV.
- To gain access to more vendor profiles available with Technavio, buy the report!
By Segment - The chemotherapy segment will be significant during the forecast period. These drugs are effective at removing cancer cells, but they can also be harmful to normal cell types, such as those in the gut and vomiting centers of the brain. Furthermore, the management of CINV typically involves a combination of antiemetic medications targeting multiple pathways involved in the development of nausea and vomiting. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Antiemetic Drug Market: Driver & Trend:
Drivers
- Rising geriatric population globally
- Growing prevalence of nausea and vomiting
- Increasing healthcare expenditure
The increasing healthcare expenditure drives the growth of the antiemetic drug market. Factors like population growth, aging demographics, technological progress, and the prevalence of chronic diseases drive the growth of health expenditures across the world. Also, the growth of the worldwide market for antiepileptic drugs is underpinned by increasing access to healthcare and coverage. Since more individuals gain access to healthcare services, the demand for various medications, including antiemetic drugs, increases. Hence, such factors drive the growth of the antiemetic drug market during the forecast period.
Identify key trends, drivers, and challenges in the market. Download sample to gain access to this information.
Related Reports:
The Antibacterial Drugs Market size is estimated to grow by USD 9,908.11 million at a CAGR of 4.21% between 2022 and 2027. Technavio has segmented the market into Route Of Administration, Drug Class, and Geography. One of the key factors driving the antibacterial drugs market growth is the rising aging population globally.
The global large molecule injectable drugs market size is estimated to grow by USD 191.45 billion at a CAGR of 7.86% between 2022 and 2027. Technavio has segmented the market into End-user, Type, and Geography. The increased focus on precision medicine and personalized therapies is a key trend in the market.
What are the key data covered in this antiemetic drug market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the antiemetic drug market between 2022 and 2027.
- Precise estimation of the antiemetic drug market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the antiemetic drug market across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of antiemetic drug market vendors.
ToC:
Excustive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Application
Market Segmentation by Drug Class
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
![](https://rt.prnewswire.com/rt.gif?NewsItemId=CG04551&Transmission_Id=202309111735PR_NEWS_USPR_____CG04551&DateId=20230911)
Share this article